Neuronal growth-inhibitory factor metallothionein-3:evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain Claire Howells, Adrian K.
Trang 1Neuronal growth-inhibitory factor (metallothionein-3):
evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain
Claire Howells, Adrian K West and Roger S Chung
Menzies Research Institute, University of Tasmania, Hobart, Australia
Introduction
Metallothioneins (MTs) are a family of unusual
cyste-ine-rich (30%), 6–7 kDa proteins synthesized
predomi-nantly by astrocytes within the brain The MT3 isoform
was first isolated and identified as a neuronal
growth-inhibitory factor (GIF) in 1991, a brain-specific protein
whose synthesis was notably deficient in the Alzheimer’s
disease (AD) brain It was found to possess a strong
ability to impair neurite outgrowth and neuronal
survival of cultured neurons, leading to its designation
as GIF It was later discovered that GIF shares
approx-imately 70% amino-acid sequence similarity with the
MT family of proteins, leading to its renaming as MT3
Most striking is the conservation within GIF of the
unique cysteine motifs found in mammalian MTs
Given that GIF shares a biochemical structure similar
to those of the other MT isoforms, it is not surprising
that GIF has the characteristic metal-binding and
reactive oxygen species (ROS) scavenging capabilities present in all MT isoforms However, GIF has also been found to exhibit several unique biological proper-ties, suggesting that this MT isoform has different and distinct functions within the brain Furthermore, the discovery and continued investigation of this brain-spe-cific MT isoform has led to intense interest in the roles
of the entire MT family in the brain, with particular focus on the role of these proteins in the injured or neurodegenerative brain
Discovery of GIF
AD is a neurodegenerative disease that leads to severe dementia and ultimately death The pathological hallmarks of the disease are intracellular neurofibril-lary tangles, dystrophic neurites or curly fibres, and
Keywords
brain injury; metals; neuronal
growth-inhibitory factor (GIF); neurodegenerative
disease; oxidative stress
Correspondence
R S Chung, PhD, Private Bag 58,
University of Tasmania, Hobart, Tasmania
7001, Australia
Fax: +61 3 62262703
Tel: +61 3 62262657
E-mail: rschung@utas.edu.au
(Received 27 November 2009, revised
13 March 2010, accepted 19 May 2010)
doi:10.1111/j.1742-4658.2010.07718.x
Neuronal growth-inhibitory factor, later renamed metallothionein-3, is one
of four members of the mammalian metallothionein family Metallothione-ins are a family of ubiquitous, low-molecular-weight, cysteine-rich proteMetallothione-ins Although neuronal growth-inhibitory factor shares metal-binding and reac-tive oxygen species scavenging properties with the other metallothioneins,
it displays several distinct biological properties In this review, we examine the recent developments regarding the function of neuronal growth-inhibi-tory factor within the brain, particularly in response to brain injury or during neurodegenerative disease progression
Abbreviations
AD, Alzheimer’s disease; Ab, b-amyloid; CNS, central nervous system; GIF, neuronal growth-inhibitory factor; KO, knockout;
MT, metallothionein; NO, nitric oxide; ROS, reactive oxygen species.
Trang 2extracellular senile amyloid plaques These physical
alterations are often accompanied by aberrant neurite
sprouting and significant neuronal loss, particularly
within the cerebral cortex and hippocampus One
explanation for this impaired neuronal survival is that
there may be decreased synthesis of a neurotrophic
factor that promotes the survival and growth of
neu-rons within the hippocampus and cerebral cortex in
the AD brain However, several studies observed that
in fact the AD brain has elevated neurotrophic activity
compared with the normal aged brain [1,2] These
studies suggested that a soluble extract from AD brain
significantly enhanced neuronal survival and neurite
outgrowth of cultured cortical neurons in comparison
with aged brain extract
It was proposed that this increased neurotrophic
activity could be a cause of the abnormal
neurofibril-lary changes that occur within the AD brain
Accord-ingly, if neurite sprouting was left unchecked, then this
process could lead to neuronal exhaustion and
eventu-ally cell death, partly explaining the vast neuronal loss
in the AD brain Further investigation of the increased
neurotrophic activity of the AD brain revealed that it
correlated with the loss of a specific neuroinhibitory
factor, rather than the presence of a neurotrophic
fac-tor This factor was later isolated and identified as
GIF, its name derived from its ability to significantly
impair neuronal survival and neurite outgrowth of
cul-tured neurons [2] It was postulated that a decrease of
GIF in AD may contribute to the aberrant neuronal
sprouting characteristic of this disease
Since its discovery, there has been considerable
sci-entific interest in understanding the expression profile
of GIF, and how the biochemical properties of GIF
confer neurotrophic functions for this protein In this
minireview we will briefly discuss these studies and
describe how GIF may influence neural recovery
fol-lowing brain injury or neurodegenerative disease
Synthesis and secretion of GIF in the
brain
Cellular and temporal localization of GIF
synthesis
Whilst the MT1 and MT2 isoforms are ubiquitously
synthesized throughout most tissues in mammals, GIF
is predominantly found within the mammalian central
nervous system (CNS) [3] The less-studied MT4
iso-form has a restricted synthesis profile, being found
almost exclusively in stratified squamous epithelia [4]
The cell-specific distribution of GIF protein and GIF
mRNA has been widely studied, with conflicting
results obtained GIF has been reported at both transcript and protein levels in astrocytes only [1,5], in neurons only [6–8], or in both neurons and astrocytes [9–11] Despite these conflicting results from a number
of studies, the current general consensus is that the GIF protein is primarily synthesized in astrocytes, where it is found predominantly in the soma and fine processes of these cells Astrocytic synthesis of GIF
is mainly found in the cortex, brainstem and spinal cord [6]
Additionally however, there are also consistent reports of neuronal synthesis of GIF, albeit at seem-ingly much lower levels than within astrocytes Neuro-nal synthesis of GIF is highly localized to specific subsets of cortical and hippocampal neurons, and is found within the axons and dendrites Neuronal pro-duction of GIF is particularly associated with granule cells of the dentate gyrus in the hippocampus, in those neurons that store and release zinc at synapses [7] While there is substantial evidence for expression of GIF mRNA in neurons from in situ hybridization studies, there is a discrepancy between the co-localiza-tion of GIF mRNA and protein, as very few studies are able to demonstrate neuronal localization of GIF
at the protein level through immunohistochemistry or similar techniques Such confirmation at the protein level has been hindered by the availability of appropri-ate GIF antibodies, and further studies are needed to resolve whether neurons synthesize basal levels of GIF protein
Neurodegenerative conditions under which GIF levels are altered
The basal level of production of GIF in the CNS is considered to be quite low, particularly in comparison with the MT1 and MT2 isoforms that are more highly expressed by astrocytes in the brain However, the levels of GIF are altered dramatically in the neurode-generative or traumatically injured brain The best-characterized example of this is for AD Indeed, many studies have analysed the amount of GIF present in
AD brain extract compared with non-demented aged controls using both mRNA and protein assays How-ever, these studies have yielded variable results, with some identifying up-regulation and others down-regu-lation of GIF levels in the AD brain compared with appropriate age-matched controls [2,12–16] For instance, immunoreactivity was shown to be reduced
in the AD cerebral cortex, specifically in the upper lay-ers of the gray matter, and this correlated with a sig-nificantly decreased number of GIF-positive astrocytes [2] Conversely, other studies have reported elevated
Trang 3GIF protein levels in AD patients when compared
with age-matched controls [14] While it is not clear
why GIF levels vary so widely in these studies, it is
thought that these results may indicate
population-based variations in GIF expression levels Hence, the
expression levels of GIF are significantly reduced in
Japanese AD patients [2,12], but do not appear to be
reduced in AD patients of North American descent
[15]
By contrast, the synthesis of GIF seems to be
down-regulated in most other neurodegenerative diseases,
including multiple-system atrophy, Parkinson’s disease,
progressive supranuclear palsy and amyotrophic lateral
sclerosis, and around senile plaques in Down
syn-drome [17] Interestingly, the level of GIF appears to
correlate with neuronal loss, as GIF immunoreactivity
disappears in areas with vast neuronal loss, but
remains in less affected areas
Given its potent neurite growth-inhibitory
proper-ties, it was predicted that the GIF levels might
corre-late with the failure of the injured brain to regenerate
Indeed, a number of studies have confirmed that levels
of GIF protein are up-regulated in reactive astrocytes
surrounding cerebral infarcts, stab wounds or
excito-toxic brain injuries For instance, GIF mRNA was
substantially up-regulated in reactive astrocytes
sur-rounding degenerated neurons following ventricular
injection of kainic acid [18] Also, GIF was elevated in
reactive astrocytes surrounding a stab wound to the
brain at 3–4 days post-injury and remained elevated
for almost a month [19,20] The increase in GIF
expression in response to these different types of brain
injury was often observed in glial cells accumulating at
the degenerating area, where the glial scar was
begin-ning to form Intriguingly, exogenously applied GIF
has been shown to induce astrocyte proliferation and
migration in vitro [14] It is possible, then, that the
up-regulation and secretion of GIF by astrocytes in the
immediate vicinity of a lesion could contribute to the
accumulation of reactive astrocytes at the injury site
Interestingly, one study has demonstrated that in the
absence of GIF [Gif gene knockout (KO) mice] there
were elevated levels of regeneration-associated
mole-cules, such as growth-associated protein 43, following
cortical cryolesion [21] Hence, evidence gathered to
date regarding GIF synthesis in response to traumatic
brain injury indicates that GIF may be involved in the
neuroinhibitory processes that are associated with glial
scar formation
It is important to note that the synthesis of MT1 and
MT2 in the injured or diseased brain is quite different
from the synthesis of GIF While GIF synthesis is
gen-erally considered to be reduced in neurodegenerative
diseases such as AD, amyotrophic lateral sclerosis and Down syndrome, MT1 and MT2 levels are consider-ably elevated in all of these conditions [22] In the trau-matically injured brain, however, the synthesis of MT1 and MT2, as well as the synthesis of GIF, are up-regu-lated by reactive astrocytes in the vicinity of the lesion [23] This suggests that these proteins may have different physiological roles in the stressed brain
Secretion of GIF The ability of GIF to inhibit neuronal survival and outgrowth occurs when the protein is applied exoge-nously to neurons However, this has raised questions over the physiological relevance of this biological func-tion of GIF, because all MT isoforms have been con-sidered as solely intracellular proteins since their discovery more than 50 years ago They lack any secre-tion signal sequences or other such extracellular traf-ficking signals, and their synthesis has generally been observed within the cytoplasm or nucleus of cells However, in 2002 it was reported that GIF is secreted
by cultured astrocytes [24] The amount of GIF secreted by the cultured astrocytes was approximately
174 ngÆmg)1 of protein, measured using ELISA [24] This study also determined that the amount of extra-cellular GIF was around 30% higher than the levels of intracellular GIF in these astrocyte cultures Further-more, the absence of cell death suggested that GIF is actively secreted by cells, although the precise mecha-nism by which GIF is secreted remains unknown Intriguingly, secretion of the MT1 and MT2 isoforms
by cultured astrocytes has also recently been reported The secretion of MT1 and MT2 by astrocytes appears
to be regulated because the basal levels of protein secretion were low and could be stimulated through cytokine-activation of cultured astrocytes [25] Whether GIF is secreted by a similar mechanism is currently not known Understanding the specific situations which stimulate GIF secretion by astrocytes will prob-ably reveal important insights into the functional roles
of this protein in the brain, and in particular its ability
to inhibit neurite outgrowth (as described above)
The functional role of GIF synthesis and secretion
in the brain Taken together, the regulation of GIF synthesis by reactive astrocytes, and its subsequent secretion under certain conditions, could be intimately involved in regulating how the brain responds to and recovers from conditions such as physical or chemical trauma Based upon the literature referred to above in this
Trang 4minireview, we propose a possible model for how GIF
might be involved in the cellular response to brain
injury (Fig 1) As neurons degenerate, the surrounding
astrocytes respond by proliferating and assume a
reac-tive phenotype GIF synthesized by reacreac-tive astrocytes
may be secreted by these cells to act upon neurons to
initially decrease neurite outgrowth in response to the
insult As the condition progresses, perturbation to the
interaction between neurons and glial cells may reduce
GIF synthesis Therefore, control over the release of
neurotrophic factors, including GIF, by the reactive
astrocytes would be compromised For instance, in the
later stages of neurodegenerative diseases the neuronal
damage may interfere with the neuroglial interactions,
lowering GIF production and secretion in reactive
astrocytes The reduction in GIF would lower the
defences against free-radical-mediated attack and
pro-tection from neuronal damage In addition, the
reduc-tion in GIF may also allow regenerative sprouting to
occur
Physiological properties of GIF
GIF has several key properties, based upon its unusual
biochemical structure, which may influence its function
in response to normal or stress-induced conditions
The relationship between protein structure and
func-tion is the subject of detailed discussion in two other
minireviews in this series [26,27] In this minireview we
will briefly describe the role of GIF in (a) regulation of
metal ion homeostasis, (b) free radical scavenging and
(c) neurite growth inhibition
Metal-binding properties of GIF and role in synaptic activity
MTs are generally considered to have an important role in maintaining the homeostasis of key metal ions within the body Like other MT isoforms, GIF binds both monovalent and divalent metal ions with high affinity They have the ability to inhibit heavy metal toxicity [i.e Cd(II), Hg(II)] and regulate the transport and storage of essential heavy metals [Cu(I) and Zn(II)] However, GIF does not seem to be essential for metal-handling within the body, because studies have reported that GIF-deficient mice were not more prone to Zn or Cd toxicity compared with control ani-mals [26] However, as GIF has been localized both intracellularly and extracellularly, it may have an important role in metal-related extracellular neuro-chemistry It is important to note that the GIF is able
to bind Cu(I) and Zn(II) concurrently For example, GIF isolated from the human brain has been found to contain both Zn(II) and Cu(I), in a Cu4Zn3-GIF struc-ture [2] The ability of GIF to bind redox-active metal ions, such as Cu(I), may suggest a crucial mechanism
of how the protein is able to reduce oxidative stress The metal-binding properties of GIF are discussed in greater detail in the two other minireviews of this series [26,27]
A clear indication of the physiological functions of GIF and its metal-binding properties has been gained from studies carried out under stress-induced condi-tions For example, GIF KO mice are highly suscepti-ble to kainic acid-induced seizures This was localized
Neuron
Low GIF
Reactive astrocyte Astrocyte
ROS
ROS
Axon injury
Fig 1 Diagrammatic model describing the possible physiological roles of GIF at differ-ent stages following a traumatic brain injury (A) Under normal conditions there is a low level of GIF synthesis within astrocytes and neurons (B) Following brain injury, astro-cytes assume the reactive phenotype and increase their synthesis of GIF Reactive astrocytes secrete GIF, which then acts to scavenge harmful ROS and blocks axon regeneration during the initial responses to the injury (C) At later stages, interference in neuroglial interactions may decrease GIF production and secretion by surrounding astrocytes The decreased levels of extra-cellular GIF would allow ROS-mediated attack on astrocytes and neurons, and may also promote excessive neurite sprouting.
Trang 5to seizure-induced injury to CA3 hippocampal
neu-rons, resulting in the GIF KO mice experiencing more
convulsions and greater mortality than their wild-type
littermates [28] GIF-overexpressing mice experience
much less kainic acid-induced brain damage compared
with controls [26], implying that GIF may play an
important protective role in response to kainic
acid-induced seizures
One explanation of how GIF can protect against
epileptic seizures is through its regulation of Zn(II)
lev-els Synaptically released zinc is thought to play a key
role in neuronal signalling, and in response to kainic
acid insult, neurons release Zn(II), as well as
gluta-mate, from the synaptic cleft Interestingly, neurons
with a high GIF mRNA content are those known to
store zinc in their axon terminals [7] In addition, the
synthesis of GIF within cultured cells led to a
signifi-cant increase in intracellular Zn(II) stores within those
cells [7] GIF, through its zinc-binding properties, may
act to recover synaptically released Zn(II) and enable
its recycling into synaptic vesicles Hence, the absence
of GIF would lead to an accumulation of
extrasynap-tic zinc, which would cause inappropriate synapextrasynap-tic
firing and subsequent seizures Interestingly, GIF may
also have a role in regulating synaptic levels of zinc, as
the GIF-deficient mice had a reduced content of Zn(II)
within a number of brain regions [28]
ROS scavenging ability of GIF
The coordination of redox-active metal ions to GIF
may indirectly prevent ROS generation through metal
chelation Conversely, all MT isoforms have the ability
to directly scavenge harmful ROS within the CNS and
other tissues ROS are highly reactive chemical
com-pounds that are constantly generated by metabolic
processes in vivo and cause serious damage to DNA,
protein and membranes containing polyunsaturated
fatty acids ROS production is a normal by-product of
metabolic activity, and under normal conditions, the
ROS are effectively quenched before being liberated to
cause damage Regulation of ROS occurs through
sev-eral ROS scavengers, or antioxidants Antioxidants
can be both enzymatic and non-enzymatic, and
func-tion to protect cells against oxidative damage Specific
antioxidants include superoxide dismutase for
superox-ide, catalase for hydrogen peroxsuperox-ide, and glutathione
peroxidase for hydrogen peroxide and lipid peroxide
In addition, there are many other non-specific
antioxi-dants, such as glutathione Another efficient general
free-radical scavenger is MT MT is a strong
nucleo-phil, because of its high cysteine content, enabling it to
efficiently bind reactive ROS [29]
MT can function as a potent scavenger of hydrogen peroxide, hydroxyl, nitric oxide (NO) and superoxide radicals Studies have shown that extracellular and intracellular GIF can protect cells from oxidative stress There have been a number of studies investi-gating the specific free-radical scavenging ability of GIF One such study reported that GIF was able to directly scavenge hydroxyl radicals generated in a Fenton-type reaction or by photolysis of hydrogen peroxide In the same study, GIF was unable to scav-enge superoxide (generated in the hypoxanthine oxi-dase reaction) or NO (generated from NOC-7) [24] The neuroprotection provided by extracellular GIF against free-radical-mediated attack was subsequently explored in vitro To induce a condition indicative of oxidative stress, neurons were grown in a hyperoxic environment Hyperoxia stimulates neuronal cells to differentiate or undergo cell death Exogenous GIF prevented the induction of neuronal differentiation, quantified by the level of neurite outgrowth in young cortical neuronal cultures The protein also prevented neuronal cell death in older cultures [24] GIF not only protected neurons from oxidative stress, but was also shown to directly quench ROS within the cul-tured neurons Using an indicator for intracellular ROS, GIF was shown to reduce ROS production in neurons
Intracellular GIF has been shown to protect against free-radical-mediated attack The knocking down of endogenous GIF by antisense oligodeoxynucleotides in cultured cortical neurons was used to examine the neu-roprotection provided by intracellular GIF against oxi-dative stress The reduction in intracellular GIF increased the rate of cortical neuronal death in a hyperoxic environment [24] In a similar study, it was reported that fibroblasts expressing GIF were more resistant to cellular cytotoxicity induced by hydrogen peroxide [30] Therefore, both intracellular and extra-cellular GIF demonstrates a strong ROS-scavenging property that is likely to protect neurons against oxi-dative damage in stress-induced conditions
Neurite growth-inhibitory property of GIF
As previously discussed, GIF displays both neurotoxic and neuroinhibitory actions The neuronal growth-inhibitory properties of GIF may have an important influence on the neural recovery from brain injury or neurodegenerative diseases The presence of GIF was neurotoxic to cultured rat cortical neurons, inhibited neurite formation in developing neurons and delayed neurite elongation [2,24,31] Importantly, GIF inhibited regenerative sprouting following axonal
Trang 6transection of mature neurons [31] However, in the
absence of brain extract (either AD or from the
nor-mal brain) GIF promotes neuron survival of cultured
cortical neurons [31]
The neuroinhibitory action of GIF is very specific to
this MT isoform and can be attributed to the small
differences in the protein sequence of this isoform
compared with all other mammalian MTs The human
GIF amino acid sequence is 70% similar to human
MT2, retaining all the 20 conserved cysteine residues
[2] The only structural differences between GIF and
MT1 and MT2 include a Cys-Pro-Cys-Pro(6–9) motif
and Thr5 in the b-domain of GIF and a different
amino acid structure in the a-domain [32] Structural
and cell biology studies have revealed that the
Cys-Pro-Cys-Pro(6–9) motif seems to be critical for the
biological activity of GIF Mutations in this motif,
specifically changing the two Pro residues to Ala and
Ser (found in human MT2) abolished the
neuroinhibi-tory activity of GIF [33] Evidence from studies using
the inactive mutant of Zn7GIF also liberated similar
results, showing that despite the contrasting biological
activities of GIF compared with MT1 and MT2, the
metal-binding affinities remain comparable However,
the precise spatial structure and the mechanism behind
the unique biological activity of GIF remain to be
elucidated
Subsequent studies have investigated whether GIF
acts in a neuroinhibitory manner when administered
directly into the brain following traumatic brain injury
In one such study, the injection of GIF into the site of
a stab wound promoted tissue repair, and the area of
the stab wound treated with GIF was significantly
smaller than those of control rats [34] Interestingly,
GIF showed dose-dependent activity, with a high dose
being detrimental to tissue repair [34] In addition,
motoneurons transfected with GIF prevented loss of
injured facial motoneurons [35] It remains to be
eluci-dated why GIF has neuroprotective functions when
administered to the injured brain, versus its
neuro-inhibitory actions upon cultured neurons
Current thoughts on the role of GIF in
AD
Since its discovery in 1991 as a factor that might be
deficient in the AD brain, a number of studies have
investigated the role of GIF in the pathogenesis of
AD While this has focussed primarily on the neuronal
inhibitory properties of GIF, several recent studies
have provided new insight into other mechanisms
through which GIF might influence the disease process
in AD
Role of the neurite growth-inhibitory properties
of GIF in AD There have been extensive studies examining the role
of GIF in AD, linked to its initial discovery as a factor deficient in the AD brain There remains no clear con-sensus on the role of GIF in the pathogenesis of AD, and therefore we will briefly review some of the current thoughts on the role of GIF in AD There are numer-ous pathological hallmarks in AD that are commonly accompanied by neuronal alterations These physical alterations include aberrant neurite sprouting and sig-nificant neuronal loss
One hypothesis for why there is pronounced neural dysfunction and death is the presence of increased neu-rotrophic activity in the AD brain It was on this assumption that GIF was first discovered as a neuro-nal growth-inhibitory factor, and a lack of GIF might contribute to the generation of neurofibrillary changes within the AD brain, including inappropriate neurite sprouting Abnormal neurite sprouting might then lead
to neuronal exhaustion and eventually cell death
In vitrostudies have clearly demonstrated the ability of GIF to block neurite outgrowth, supporting the initial proposal of Uchida et al [2] that a lack of GIF might
be involved in AD pathogenesis However, postmor-tem human studies have provided mixed results on the level of GIF present in the AD brain The generation
of GIF KO or GIF overexpressing mice with tau-based experimental mouse models of AD might pro-vide considerable insight into the potential role of GIF
in neurofibrillary changes associated with AD
Potential role of metal-binding/exchange properties of GIF in AD
One of the primary pathological hallmarks of AD is the formation of b-amyloid (Ab) plaques, composed primarily of Ab(1–40) and Ab(1–42) peptides, which associate to form abnormal extracellular deposits of fibrils and amorphous aggregates [36] Ab is a metallo-protein that possesses high- and low-affinity Cu(I)-and Zn(II)-binding sites Furthermore, metal ion homeostasis within the AD brain is dramatically unbalanced and is proposed to be involved in the pathology of Ab For example, within the amyloid pla-ques the Cu(I) and Fe(III)⁄ Zn(II) concentrations were
0.4 and 1 mm respectively, compared with 70 and 340–350 lm, respectively, in healthy neocortical paren-chyma [37] The close association between metal ions and Ab has prompted many groups to investigate numerous metal chelators to establish whether they have the potential to modify Ab pathogenesis in AD
Trang 7Intriguingly, GIF has strong Cu(I)- and
Zn(II)-bind-ing efficiencies, suggestZn(II)-bind-ing that it may be able to
mod-ify metal-induced Ab aggregation in AD In this
context, it has recently been reported that Zn7GIF was
shown to remove Cu from aggregated Ab(1–40)-Cu(II)
with the concomitant binding of Zn, leading to the
for-mation of SDS-soluble monomeric zinc-bound Ab and
soluble copper-bound GIF [38] Therefore, the metal
swap led to simultaneous modification of the final
form of Ab(1–40) and suggests that it caused the
de-aggregation of Ab In a therapeutic context, this
indicates that MT might potentially promote the
clear-ance of Ab plaques However, it is important to note
that recent therapeutic approaches have been
success-ful in clearing Ab plaques in clinical trials, but not for
reducing neurodegeneration in the AD brain [39]
It is important to note that while Ab aggregation can
be induced by both Cu(II) and Zn(II), only the
Cu(II)-induced aggregation of Ab is toxic The neurotoxicity of
Cu(II)-induced Ab aggregation is related to the
genera-tion of ROS through the redox cycling of Cu In this
regard, GIF has been demonstrated to not only prevent
Ab aggregation, but also block the generation of ROS
by Ab-Cu(II) [27,38] Therefore, the ability of GIF to
redox-silence metal ions and directly scavenge ROS
(dis-cussed above) provide two distinct mechanisms through
which GIF can act to protect against Ab pathogenesis
and neurotoxicity in AD (Fig 2)
Conclusion
The discovery of a brain-specific MT isoform, GIF, in
1991, sparked considerable interest in understanding
the role of all MTs in the brain, and particularly
within the injured or diseased brain In the case of GIF, the protein has many neuroprotective properties that could provide vital protection during stress-induced conditions Studies have already focused on the ability
of GIF to protect against Ab pathology and neurotoxic-ity in AD, with promising results By contrast, GIF also demonstrates a unique neuroinhibitory property, which may promote cellular survival and repair following injury, but could also be detrimental in neurodegenera-tive diseases The studies to date have only just started
to investigate and understand the physiological roles of GIF within the brain Further studies are required to determine the function of GIF within the normal, injured and neurodegenerative brain, and to establish the therapeutic potential of the protein
Acknowledgements
This work was supported by an Australian Research Council (ARC) Discovery Project Grant (DP0556630; RSC), and funding from the Jack & Ethel Goldin Foundation (Alzheimer’s Australia) RSC holds an ARC Research Fellowship
References
1 Uchida Y & Tomonaga M (1989) Neurotrophic action
of Alzheimer’s disease brain extract is due to the loss of inhibitory factors for survival and neurite formation of cerebral cortical neurons Brain Res 481, 190–193
2 Uchida Y, Takio K, Titani K, Ihara Y & Tomonaga M (1991) The growth inhibitory factor that is deficient in the Alzheimers-disease brain is a 68-amino acid metallo-thionein-like protein Neuron 7, 337–347
Cu- GIF
+
Reducing agent
Reducing agent
Zn- GIF
+
+ Aβ-Zn i)
A ββ-Cu(II) A β-Cu(I) A β-Cu(II) A β-Cu(II) A β-Cu(I) A β-Cu(II)
+
ii)
Zn-GIF Cu-GIF
)
Fig 2 A diagrammatic model describing the possible protective properties of GIF against Ab pathogenesis and neurotoxicity in Alzheimer’s disease (A) In the presence of a reducing agent, the copper coordinated to the Ab can undergo redox cycling to produce harmful ROS that damage the neurons (B) MT is likely to protect against Ab-Cu(II) by a number of mechanisms: Zn7GIF is proposed to undergo a transmetalla-tion event with the Ab-Cu(II), which removes the redox-active Cu(II) from the Ab, coordinating it to MT as redox-stable Cu(I), while simulta-neously Ab coordinates redox-inert Zn This event would prevent the generation of ROS ZnGIF or CuGIF could also directly scavenge ROS.
Trang 83 Palmiter RD, Findley SD, Whitmore TE & Durnam
DM (1992) MT-III, a brain-specific member of the
metallothionein gene family Proc Natl Acad Sci U S A
89, 6333–6337
4 Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly
EJ, Zambrowicz BP & Palmiter RD (1994) Induction of
a new metallothionein isoform (MT-IV) occurs during
differentiation of stratified squamous epithelia
Biochemistry 33, 7250–7259
5 Nakajima K & Suzuki K (1995) Immunochemical
detec-tion of metallothionein in brain Neurochem Int 27,
73–87
6 Choudhuri S, Kramer KK, Berman NE, Dalton TP,
Andrews GK & Klaassen CD (1995) Constitutive
expression of metallothionein genes in mouse brain
Toxicol Appl Pharmacol 131, 144–154
7 Masters BA, Quaife CJ, Erickson JC, Kelly EJ,
Froelick GJ, Zambrowicz BP, Brinster RL & Palmiter
RD (1994) Metallothionein-III is expressed in neurons
that sequester zinc in synaptic vesicles J Neurosci 14,
5844–5857
8 Gong YH & Elliott JL (2000) Metallothionein
expres-sion is altered in a transgenic murine model of familial
amyotrophic lateral sclerosis Exp Neurol 162, 27–36
9 Yamada M, Hayashi S, Hozumi I, Inuzuka T, Tsuji S
& Takahashi H (1996) Subcellular localization of
growth inhibitory factor in rat brain: light and electron
microscopic immunohistochemical studies Brain Res
735, 257–264
10 Yuguchi T, Kohmura E, Sakaki T, Nonaka M,
Yamada K, Yamashita T, Kishiguchi T, Sakaguchi T &
Hayakawa T (1997) Expression of growth inhibitory
factor mRNA after focal ischemia in rat brain J Cereb
Blood Flow Metab 17, 745–752
11 Zheng H, Berman NE & Klaassen CD (1995) Chemical
modulation of metallothionein I and III mRNA in
mouse brain Neurochem Int 27, 43–58
12 Tsuji S, Kobayashi H, Uchida Y, Ihara Y & Miyatake
T (1992) Molecular cloning of human growth inhibitory
factor cDNA and its down-regulation in Alzheimer’s
disease EMBO J 11, 4843–4850
13 Yu WH, Lukiw WJ, Bergeron C, Niznik HB & Fraser
PE (2001) Metallothionein III is reduced in Alzheimer’s
disease Brain Res 894, 37–45
14 Carrasco J, Giralt M, Molinero A, Penkowa M, Moos
T & Hidalgo J (1999) Metallothionein (MT)-III:
generation of polyclonal antibodies, comparison with
MT-I+II in the freeze lesioned rat brain and in a
bioassay with astrocytes, and analysis of Alzheimer’s
disease brains J Neurotrauma 16, 1115–1129
15 Erickson JC, Sewell AK, Jensen LT, Winge DR &
Palmiter RD (1994) Enhanced neurotrophic activity in
Alzheimers-disease cortex is not associated with
down-regulation of metallothionein-III (GIF) Brain
Res 649, 297–304
16 Amoureux MC, Van Gool D, Herrero MT, Dom R, Colpaert FC & Pauwels PJ (1997) Regulation of metallothionein-III (GIF) mRNA in the brain of patients with Alzheimer disease is not impaired Mol Chem Neuropathol 32, 101–121
17 Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, Furuta H & Ogawa N (2001) Localiza-tion, regulaLocaliza-tion, and function of metallothionein-III⁄ growth inhibitory factor in the brain Acta Med Okayama 55, 1–9
18 Kim D, Kim EH, Kim C, Sun W, Kim HJ, Uhm CS, Park SH & Kim H (2003) Differential regulation of metallothionein-I, II, and III mRNA expression in the rat brain following kainic acid treatment Neuroreport
14, 679–682
19 Hozumi I, Inuzuka T, Hiraiwa M, Uchida Y, Anezaki
T, Ishiguro H, Kobayashi H, Uda Y, Miyatake T & Tsuji S (1995) Changes of growth inhibitory factor after stab wounds in rat brain Brain Res 688, 143–148
20 Hozumi I, Inuzuka T, Ishiguro H, Hiraiwa M, Uchida
Y & Tsuji S (1996) Immunoreactivity of growth inhibi-tory factor in normal rat brain and after stab wounds–
an immunocytochemical study using confocal laser scan microscope Brain Res 741, 197–204
21 Carrasco J, Penkowa M, Giralt M, Camats J, Molinero
A, Campbell IL, Palmiter RD & Hidalgo J (2003) Role
of metallothionein-III following central nervous system damage Neurobiol Dis 13, 22–36
22 Hidalgo J, Aschner M, Zatta P & Vasa´k M (2001) Roles of the metallothionein family of proteins in the central nervous system Brain Res Bull 55, 133–145
23 Chung RS, Adlard PA, Dittmann J, Vickers JC, Chuah
MI & West AK (2004) Neuron-glia communication: metallothionein expression is specifically up-regulated
by astrocytes in response to neuronal injury J Neuro-chem 88, 454–461
24 Uchida Y, Gomi F, Masumizu T & Miura Y (2002) Growth inhibitory factor prevents neurite extension and the death of cortical neurons caused by high oxygen exposure through hydroxyl radical scavenging J Biol Chem 277, 32353–32359
25 Chung RS, Penkowa M, Dittmann J, King CE, Bartlett
C, Asmussen JW, Hidalgo J, Carrasco J, Leung YKJ, Walker AK et al (2008) Redefining the role of thionein within the injured brain – extracellular metallo-thioneins play an important role in the astrocyte-neuron response to injury J Biol Chem 283, 15349–15358
26 Faller P (2010) Neuronal growth inhibitory factor (metallothionein-3): reactivity and structure of metal-thiolate clusters FEBS J 277, 2921–2930
27 Ding ZC, Ni FY & Huang ZX (2010) Neuronal growth inhibitory factor (metallothionein-3): structure-function relationships FEBS J 277, 2912–2920
28 Erickson JC, Hollopeter G, Thomas SA, Froelick GJ & Palmiter RD (1997) Disruption of the
Trang 9metallothionein-III gene in mice: analysis of brain zinc, behavior, and
neuron vulnerability to metals, aging, and seizures
J Neurosci 17, 1271–1281
29 Meloni G, Faller P & Vasak M (2007) Redox silencing
of copper in metal-linked neurodegenerative disorders
reaction of Zn(7)metallothionein-3 with Cu2+ions
J Biol Chem 282, 16068–16078
30 You HJ, Lee KJ & Jeong HG (2002) Overexpression of
human metallothionein-III prevents hydrogen
peroxide-induced oxidative stress in human fibroblasts FEBS
Lett 521, 175–179
31 Chung RS, Vickers JC, Chuah MI, Eckhardt BL &
West AK (2002) Metallothionein-III inhibits initial
neurite formation in developing neurons as well as
postinjury, regenerative neurite sprouting Exp Neurol
178, 1–12
32 Sewell AK, Jensen LT, Erickson JC, Palmiter RD &
Winge DR (1995) Bioactivity of metallothionein-3
correlates with its novel beta-domain sequence rather
than metal-binding properties Biochemistry 34,
4740–4747
33 Hasler DW, Jensen LT, Zerbe O, Winge DR & Vasak
M (2000) Effect of the two conserved prolines of human
growth inhibitory factor (metallothionein-3) on its
biological activity and structure fluctuation: comparison
with a mutant protein Biochemistry 39, 14567–14575
34 Hozumi I, Uchida Y, Watabe K, Sakamoto T & Inuzuka T (2006) Growth inhibitory factor (GIF) can protect from brain damage due to stab wounds in rat brain Neurosci Lett 395, 220–223
35 Sakamoto T, Kawazoe Y, Uchida Y, Hozumi I, Inuzuka T & Watabe K (2003) Growth inhibitory factor prevents degeneration of injured adult rat motoneurons Neuroreport 14, 2147–2151
36 Mattson MP (2004) Pathways towards and away from Alzheimer’s disease Nature 430, 631–639
37 Lovell MA, Robertson JD, Teesdale WJ, Campbell JL
& Markesbery WR (1998) Copper, iron and zinc in Alz-heimer’s disease senile plaques J Neurol Sci 158, 47–52
38 Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, Teissie J, Faller P & Vasak M (2008) Metal swap between Zn-7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity Nat Chem Biol 4, 366–372
39 Holmes C, Boche D, Wilkinson D, Yadegarfur G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW et al (2008) Long-term effects of Ab 42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo controlled phase I trial Lancet
372, 216–223